Cell Line News and Research

RSS

Whitehead researchers develop new type of genetic screen for human cells

Whitehead researchers have developed a new type of genetic screen for human cells to pinpoint specific genes and proteins used by pathogens, according to their paper in Science.

27 Nov 2009

'Suicide gene E' reduces potent drug dosage in cancer patients

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

25 Nov 2009

Gonorrhea medication may help fight cancer

Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer.

6 Nov 2009

Nanoparticles may cause DNA damage across a cellular barrier

Scientists have shown in the laboratory that metal nanoparticles damaged the DNA in cells on the other side of a cellular barrier. The nanoparticles did not cause the damage by passing through the barrier, but generated signalling molecules within the barrier cells that were then transmitted to cause damage in cells the other side of the barrier.

5 Nov 2009

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

Two teams of UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their stem cell based strategies for treating diabetes and brain tumors.

30 Oct 2009

Fresenius Kabi to license its proprietary HESylation Technology to Octapharma

Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation® Technology to develop a HESylated recombinant protein.

29 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Chrysanthemum indicum extract holds promise for treating human cancer

A series of studies have demonstrated that Chrysanthemum indicum possesses antimicrobial, antiinflammatory, immunomodulatory, and neuroprotective effects. Recently, much attention has been devoted to the anticancer activity of Chrysanthemum indicum, especially in hepatocellular carcinoma (HCC). However, its anticancer mechanism of action is still not clear and needs further investigation.

19 Oct 2009

The Automation Partnership's ambr technology to be previewed at the Bioprocess International Conference

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, is exclusively previewing its Advanced Microscale BioReactor (ambr™) technology on Booth 914 at the Bioprocess International Conference in Raleigh, USA.

13 Oct 2009

Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

Selexis SA and Irvine Scientific Inc. announced today plans to jointly present results of a recent collaborative effort combining the Selexis SURE Cell Line Development Programs(TM) and the Irvine IS CHO Culture System, demonstrating the rapid production of gram quantities of monoclonal antibodies from stable CHO production cell lines.

12 Oct 2009

Vitro Diagnostics' research reveals expanded uses of its fluorescent stem cells

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced completion of a research report concerning its fluorescent stem cells, http://www.vitrobiopharma.com/wp-content/uploads/2009/10/fluorescent-msc-10-3.pdf. This report revealed transfer of fluorescent to differentiated cells including chondrocytes, cells responsible for making cartilage.

7 Oct 2009

Researchers identify that KLF17 gene with Id1 gene can regulate breast cancer metastasis

Researchers at The Wistar Institute have identified a key gene (KLF17) involved in the spread of breast cancer throughout the body. They also demonstrated that expression of KLF17 together with another gene (Id1) known to regulate breast cancer metastasis accurately predicts whether the disease will spread to the lymph nodes.

6 Oct 2009

Sigma-Aldrich and Sangamo Biosciences extend license agreement for ZFP technology

Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals.

5 Oct 2009

Parathyroid gland transplants may prevent untreatable form of bone loss

An early laboratory success is taking University of Michigan researchers a step closer to parathyroid gland transplants that could one day prevent a currently untreatable form of bone loss associated with thyroid surgery.

30 Sep 2009

Misregulation of SPAK protein may contribute to B-cell lymphoma development

A group led by Dr. Michael Teitell at UCLA has demonstrated that misregulation of the protein SPAK may contribute to B-cell lymphoma development. Their report can be found in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

Nanodiamonds advance anticancer gene therapy

Gene therapy holds promise in the treatment of cancer as well as a large number of other diseases. However, developing a scalable system for delivering genes to cells both efficiently and safely has been challenging. Now, two teams of researchers have developed versatile nanotechnology-enabled platforms that could get therapeutic genes safely and efficiently into cancer cells.

23 Sep 2009

SEA technology to increase potency of monoclonal antibodies

Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.

23 Sep 2009

Cyntellect announces commercial availability of Stem Cell Manager

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, announced today the commercial availability of Stem Cell Manager powered by LEAP.

16 Sep 2009

Molecular mechanism responsible for transition of non-invasive breast cancer into invasive disease discovered

Active, but non-invasive breast cancer is set free to roam as invasive breast cancer when an overexpressed protein converts it to a different cell type, scientists at The University of Texas M. D. Anderson Cancer Center report in the Sept. 9 issue of the journal Cancer Cell.

9 Sep 2009

Selexis SA and NKT Therapeutics sign research services agreement

Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM).

2 Sep 2009